Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?
复制标题
DOI：
10.1093/jac/dkab189
复制
发表时间：
2021-06-18
影响因子：
5.2
通讯作者：
Owen, Andrew
中科院分区：
文献类型：
--
作者：
Hiscox, Julian A.;Khoo, Saye H.;Owen, Andrew
本文简要概述了抗病毒治疗的耐药性以及关键SARS-CoV-2病毒序列的已知和紧急变异性。其目的是促进对在广泛推出SARS-CoV-2抗病毒药物之前考虑耐药性的必要性的审议。许多现有的候选药物具有涉及药物靶点的作用机制，可能对未来的药物开发至关重要。随着针对其他肺部病毒（如流感病毒）的单一疗法的部署，以及艾滋病毒关键药物靶点的突变，耐药性迅速出现，从而影响了一类药物中多种药物的疗效。SARS-CoV-2的耐药性潜力尚未得到严格的辩论或评估，我们呼吁在广泛推出COVID-19治疗和预防的单一疗法之前，对这一潜在的重要未来威胁进行更多的学术和行业研究。
This article provides a brief overview of drug resistance to antiviral therapy as well as known and emergent variability in key SARS-CoV-2 viral sequences. The purpose is to stimulate deliberation about the need to consider drug resistance prior to widespread roll-out of antivirals for SARS-CoV-2. Many existing candidate agents have mechanisms of action involving drug targets Likely to be critical for future drug development. Resistance emerged quickly with monotherapies deployed for other pulmonary viruses such as influenza virus, and in HIV mutations in key drug targets compromised efficacy of multiple drugs within a class. The potential for drug resistance in SARS-CoV-2 has not yet been rigorously debated or assessed, and we call for more academic and industry research on this potentially important future threat prior to widespread roll-out of monotherapies for COVID-19 treatment and prevention.